We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





COVID-19 Rapid Antigen Test Provides End-to-End Digital Screening Solution

By LabMedica International staff writers
Posted on 03 Jun 2021
A new COVID-19 antigen test provides a full end-to-end digital screening solution to prevent further outbreaks.

iXensor’s (Taipei, Taiwan) PixoTest POCT COVID-19 Antigen Test has received the CE-IVD mark. More...
The iXensor’s PixoTest solution comprises a palm-sized analyzer that reads test results accurately, a digital health pass App, an Admin App, and a HIPAA-grade health management web portal. The fully digitized testing and reporting design shortens the test-to-report time to 15 minutes. In addition to overcoming the lab testing limitations, the solution allows for scaling in large screening settings, thereby enabling business continuity and reopening.

With the PixoTest POCT Analyzer reading test results objectively, healthcare organizations and corporations can minimize the risks of having false-negative cases compared to rapid tests interpreted by human eyes. The analyzer transmits test results simultaneously to the PixoHealth Pass App users via an encrypted QR code. The digital health pass also records App users’ vaccination certificates, helping free movement in the upcoming summer holiday season. The PixoHealth Pass Admin App is designed for organizations to verify the authenticity of PixoTest test results with one simple scan. The admin app protects organizations’ safety amidst the pandemic by validating the cheat-proof, encrypted results shown on PixoHealth Pass App.

“We are deploying iXensor’s core PixoTech technology to develop the smartphone-based self-test that can perform COVID-19 testing and tracking, anywhere at any time,” said Dr. Peter Fitzgerald, Chairman of iXensor and Emeritus Professor of Medicine School at Stanford University. “I believe having COVID-19 at-home test will drastically cut many transmission paths to stop the pandemic.”

Related Links:
iXensor


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.